JSS Sustainable Equity - Future Health P CHF acc

Reference Data

ISIN LU2041625497
Valor Number 49498046
Bloomberg Global ID
Fund Name JSS Sustainable Equity - Future Health P CHF acc
Fund Provider J. Safra Sarasin Investmentfonds AG Basel, Switzerland
Phone: +41 58 317 44 44
Web: www.jsafrasarasin.com
Fund Provider J. Safra Sarasin Investmentfonds AG
Representative in Switzerland J. Safra Sarasin Investmentfonds AG
Basel
Phone: +41 58 317 44 00
Distributor(s) Bank J. Safra Sarasin AG
Basel
Phone: +41 58 317 44 00
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The investment objective of the fund is to achieve long-term capital growth. The Reference Currency of the Sub-Fund is the US Dollar (USD).
Peculiarities

Fund Prices

Current Price * 97.88 CHF 10.02.2025
Previous Price * 97.78 CHF 07.02.2025
52 Week High * 102.21 CHF 16.07.2024
52 Week Low * 90.40 CHF 19.11.2024
NAV * 97.88 CHF 10.02.2025
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 115,003,891
Unit/Share Assets *** 11,795,306
Trading Information SIX

Performance

YTD Performance +5.77% 31.12.2024
10.02.2025
1 month +3.02% 10.01.2025
10.02.2025
3 months +3.03% 12.11.2024
10.02.2025
6 months +1.45% 12.08.2024
10.02.2025
1 year +6.75% 12.02.2024
10.02.2025
2 years -3.80% 10.02.2023
10.02.2025
3 years -13.82% 10.02.2022
10.02.2025
5 years -3.95% 10.02.2020
10.02.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Eli Lilly and Co 6.53%
UnitedHealth Group Inc 6.04%
Danaher Corp 5.59%
Sanofi SA 5.11%
Boston Scientific Corp 4.97%
Johnson & Johnson 4.55%
Gilead Sciences Inc 4.00%
AstraZeneca PLC 3.82%
Novo Nordisk AS Class B 3.66%
UCB SA 3.24%
Last data update 31.12.2024

Cost / Risk

TER 1.98%
TER date 30.04.2024
Performance Fee ***
PTR
Max. Management Fee *** 2.00%
Ongoing Charges *** 1.92%
SRRI ***
SRRI date *** 31.01.2025

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 *** GMOs

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)